Shionogi Company Limited

Naotake Kobayashi

Akira Kato

Kazuo Ueda

Akira Yukimasa

Akihiro Hori

Naohiro Itoh

Gaku Sakaguchi

Hidekazu Haraguchi

Ken Yasui

Shinji Suzuki

Yasuhiko Kanda

Yuji Koriyama

Toru Yamada

Tomoyuki Ogawa

Hiroyuki Kai

Koji Masuda

Eiichi Kojima

Shuichi Sugiyama

Manabu Katou

Toshihiro Wada

Yoshikazu Sasaki

Masaaki Uenaka

Masahiko Nagai

Kenji Takaya

Yuuji Kooriyama

Naoki Ohyabu

Yuji Nishiura

Takatsugu Inoue

Masafumi Iwatsu

Keisuke Miyazaki

Yutaka Tomida

Kana Kurahashi

Masataka Fumoto

Yoshio Hato

Kentarou Asahi

Masahide Ohdan

Tomomi Urabe

Provided are a novel compound having an antagonistic activity for the P2Xreceptor, and a pharmaceutical composition having an antagonistic activity for the P2Xreceptor. A compound represented by Formula (I): wherein Zis C(R) or the like; Ris a hydrogen atom or the like; Zis C(R)(R) or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then Ris absent; Rand Rare each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Yis O or the like; Ris a group represented by the formula: &#x2014;(C(R)(R))&#x2014;R; Ris a hydrogen atom or the like; Rand Ris each independently a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R) or the like; Ris a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.

Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same

Provided are a novel compound having an antagonistic activity for the P2Xreceptor, and a pharmaceutical composition having an antagonistic activity for the P2Xreceptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): 

Alkylene derivatives

The present invention is related to a compound represented by formula (I) wherein Ris a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is &#x2014;N(R)&#x2014;, &#x2014;O&#x2014;, or &#x2014;S&#x2014;; Y is &#x2550;C(R)&#x2014;, or &#x2550;N&#x2014;; Z is &#x2014;N(R)&#x2014;, &#x2014;O&#x2014;, or &#x2014;S&#x2014;;

Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity

A composition having BACE 1 inhibitory activity containing a compound represented by the formula (I): 

Aminodihydrothiazine derivatives

A pharmaceutical composition for treating Alzheimer's disease containing a compound represented by the general formula (I): 

Pharmaceutical composition for treating alzheimer's disease

A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): 

A pharmaceutical composition for treating Alzheimer's disease containing a compound represented by the general formula (I); wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;

Pharmaceutical composition for treating Alzheimer's disease

A composition having BACE 1 inhibitory activity containing a compound represented by the formula (I): wherein ring A is an optionally substituted heterocyclic group;E is lower alkylene;X is S;Ris a hydrogen atom or lower alkyl;R, R, R, R, Rand Ris each independently a hydrogen atom, halogen, or hydroxy etc.;n and m are each independently an integer of 0 to 3;n+m is an integer of 0 to 3;Ris a hydrogen atom or substituted lower alkyl;or its pharmaceutically acceptable salt thereof.

A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;

Process for producing 4-thiazolylmethyl derivative

Growing community of inventors

Osaka, Japan

Naotake Kobayashi